Advanced search
Start date
Betweenand

Risk acceptance in multiple sclerosis paciente on natalizumabe treatment

Grant number: 15/22721-7
Support type:Scholarships in Brazil - Scientific Initiation
Effective date (Start): February 01, 2016
Effective date (End): January 31, 2017
Field of knowledge:Health Sciences - Medicine - Medical Clinics
Principal researcher:Denis Bernardi Bichuetti
Grantee:Carolina Azze Franco
Home Institution: Escola Paulista de Medicina (EPM). Universidade Federal de São Paulo (UNIFESP). Campus São Paulo. São Paulo , SP, Brazil

Abstract

In the last decade, new drugs for multiple sclerosis have been tested and approved. Among them is natalizumab, that despite its high efficacy has its use limited by the risk of developing progressive multifocal leukoencephalopathy. By applying, a questionnaire with inclusion of patients diagnosed with relapsing-remitting multiple sclerosis, we aimed to assess how patients assess the risks of treatment with natalizumab and the factors involved in this evaluation.

News published in Agência FAPESP Newsletter about the scholarship:
Articles published in other media outlets (0 total):
More itemsLess items
VEICULO: TITULO (DATA)
VEICULO: TITULO (DATA)